Spinal cord injuries cause severe disability because nerve cells rarely regenerate and scarring prevents nerve fibres from growing back. Existing therapies try to use electrical stimulation to help transplanted stem cells form new neurons, but they require implanted electrodes and the cells do not always survive or integrate well.
Researchers in Zurich published a method that combines therapeutic stem cells with magnetoelectric nanoparticles to make biohybrid microrobots called NPCbots. The team joins neural progenitor cells (early nerve cells) derived from induced pluripotent stem cells with nanoparticles that have an inner magnetic layer and an outer layer that converts magnetic responses into electrical signals. The particles let external magnetic fields guide and stimulate the cells without implanted electrodes.
Production happens on a small lab-on-a-chip surface and the team scales fabrication by running systems in parallel. Tests in zebrafish showed near‑normal swimming in three days. In mice with severed spinal cords, reconnection at the injury and improvements in gait and coordination appeared after 28 days, with no clear adverse or immune reactions. Further work is needed before human trials and to study long-term particle fate.
Difficult words
- regenerate — to grow again after injury or damage
- scarring — scar tissue that blocks healing and new growth
- transplant — to place tissue or cells into a bodytransplanted
- implant — to put a device or material inside bodyimplanted
- integrate — to join and work together with other cells
- magnetoelectric nanoparticle — tiny particle that converts magnetic signals to electrical onesmagnetoelectric nanoparticles
- neural progenitor cell — early nerve cell that can become other nerve cellsneural progenitor cells
- lab-on-a-chip — small device that does lab tests on a tiny chip
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- What are the advantages of guiding and stimulating cells with external magnetic fields instead of implanted electrodes?
- What safety or long-term questions should researchers study before human trials?
- How might this biohybrid microrobot approach change treatment for people with spinal cord injuries?
Related articles
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
Engineered bacteria produce tagatose sweetener
Tufts researchers engineered Escherichia coli to make tagatose, a rare sugar that can substitute for table sugar. They used a slime mold enzyme and another enzyme to convert glucose, producing higher yields; tagatose is low‑calorie and FDA‑recognized as safe.
